News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Amkor (AMKR) recommended buy ahead of Q3 earnings on Oct 26, citing Nvidia-driven advanced packaging demand.
  • AMKR trades at a discount to semiconductor peers, implying potential P/E re-rating if revenues improve.
  • Technicals show oversold momentum, positioning AMKR as a mid-term swing trade with entry, stop, and target guidance.
  • Key catalyst: Nvidia-linked advanced packaging adoption could increase AMKR revenue visibility.
  • Primary risk: execution failure could derail earnings and re-rating.
  • Secondary risk: semiconductor cyclicality may limit sustained valuation gains.

Latest Articles

Three deeply discounted stocks near 52-week lows that may rebound strongly

Three deeply discounted stocks near 52-week lows that may rebound strongly

A focused screen found three large-cap names trading at steep discounts to their 52-week highs and with substantial fair-value upside under InvestingPro models. Lululemon (LULU) sits at a 9.3x P/E and 81.1% fair-value upside; Charter Communications (CHTR) trades at 3.8x earnings with a 72.8% gap to fair value; and Fiserv (FISV) is down 63.2% from i…

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., announced the filing of two U.S. patent applications for its lead assets EL-22 and EL-32, aimed at preserving lean muscle mass during long-duration spaceflight by targeting muscle loss caused by microgravity. These filings extend the company's intellectual property portfolio beyond terres…

T3 Defense Enters the UAV and Counter-UAV (C-UAV) Platform Market

T3 Defense Enters the UAV and Counter-UAV (C-UAV) Platform Market

T3 Defense Inc., through its subsidiary Rimon Agencies Ltd., is entering the UAV and counter-UAV platform market by offering configurable mobile infrastructure platforms designed to deploy and support drone and counter-drone systems without permanent infrastructure. This move leverages Rimon's engineering experience and targets a growing defense ma…

Emerging-market currencies climb to fresh peaks as dollar weakness persists

Emerging-market currencies climb to fresh peaks as dollar weakness persists

Emerging-market currencies hit record highs on Friday and were poised for an eighth consecutive weekly advance as broad dollar weakness supported demand for risk-sensitive assets. A renewed rise in U.S. Treasury yields followed a brief government intervention, while concerns over U.S. fiscal dynamics and geopolitical tensions in the Gulf kept infla…

NFT LTD Announces Pricing of US$2.0 Million Public Offering

NFT LTD Announces Pricing of US$2.0 Million Public Offering

NFT Limited, an operator of an online art trading platform, announced the pricing of a $2 million public offering consisting of 437,957 units at $4.60 each. Each unit includes one Class A Ordinary Share or a pre-funded warrant and one common warrant exercisable at $4.60, valid for five years. The proceeds will support the company's working capital …

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical to jointly commercialize two biosimilar candidates—AVT34 (biosimilar to Imfinzi®) and AVT87 (biosimilar to Hemlibra®)—in the United States and selected Asian markets. The deal includes semi-exclusive U.S. rights for both companies and exclusive rights…

MicroCloud Hologram Inc. Announces Acquisition of 140,268 MSTR Shares Through Structured Note Investment Product, Continuing Its Strategic Investment in Bitcoin-Related Assets

MicroCloud Hologram Inc. Announces Acquisition of 140,268 MSTR Shares Through Structured Note Investment Product, Continuing Its Strategic Investment in Bitcoin-Related Assets

MicroCloud Hologram Inc. announced the acquisition of 140,268 shares of MicroStrategy Incorporated (MSTR) common stock through the maturity and settlement of a structured note investment product worth approximately $15.76 million. The company views this as a strategic move to strengthen its position in Bitcoin and digital asset-related opportunitie…

Space-Eyes Announces Four Distinguished Appointments to Post-Combination Board of Directors Reflecting Deep National Security, Intelligence, Defense and Global Capital Markets Expertise

Space-Eyes Announces Four Distinguished Appointments to Post-Combination Board of Directors Reflecting Deep National Security, Intelligence, Defense and Global Capital Markets Expertise

Space-Eyes, an AI-driven geospatial intelligence and counter-UAS company, announced the appointments of four distinguished leaders to its post-combination board. These appointments bring deep expertise in national security, defense, strategy, aerospace manufacturing, and global finance as Space-Eyes prepares to become a publicly traded company on N…

iRhythm: Algorithmic Margin Inflection Makes This a Tactical Long

iRhythm: Algorithmic Margin Inflection Makes This a Tactical Long

iRhythm is entering a different profit cycle. Revenue growth remains healthy while algorithm-driven margin expansion — not new hardware — is the clearest lever to lift profitability. Market skepticism after product delays and a cyber incident creates an actionable asymmetric trade. We outline a mid-term (45 trading days) long with concrete levels a…

Marvell’s Rally: Valuation Questions as Oppenheimer Raises Target to $300

Marvell’s Rally: Valuation Questions as Oppenheimer Raises Target to $300

Oppenheimer raised its Marvell Technology (MRVL) price target to $300 from $250, suggesting about 19.5% upside from the prevailing $251.01 share price. The upgrade centers on a structural artificial intelligence thesis in which custom ASIC revenue is expected to double to more than $4 billion next year and to surpass $10 billion by calendar year 20…

Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday

Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday

Splash Beverage Group, trading on NYSE American as SBEV, is changing its name to Endovia Health Sciences, Inc. and adopting a new ticker symbol, EDVA, starting August 24, 2026. This rebranding reflects the company’s strategic transformation from beverage operations into a diversified cannabinoid-based health sciences platform. Endovia focuses on th…

Quantum X Labs Announces Additional Advancement in Quantum Error Correction Using NVIDIA CUDA-Q with New Results on Google’s Dataset

Quantum X Labs Announces Additional Advancement in Quantum Error Correction Using NVIDIA CUDA-Q with New Results on Google’s Dataset

Quantum X Labs announced enhanced performance of its AI-assisted quantum error-correction decoder using Google’s public surface-code dataset from real quantum hardware. The decoder, trained exclusively on synthetic data, outperformed benchmark algorithms, supporting the company’s progress toward reliable, scalable, and real-time quantum error corre…